People: aTyr Pharma Inc (LIFE.OQ)
19 Oct 2020
Ms. Jill M. Broadfoot CPA serves as Chief Financial Officer of the Company. Prior to joining aTyr, from January 2017 to July 2018, Ms. Broadfoot served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc. where she was responsible for establishing operations for the U.S.-based pharmaceutical and bioceuticals entities as well as the establishment of operations, corporate governance, finance and accounting and investor relations functions, among others. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals plc, from May 2016 to January 2017. While at GW Pharmaceuticals, her responsibilities included establishing U.S. commercial operations and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc., from October 2004 to March 2013, where she had oversight of finance, investor relations, manufacturing, information technology, human resources, and business development. Before joining Vical, Ms. Broadfoot held various positions at DJO Global, Inc., most recently as Vice President of Finance. Ms. Broadfoot also served as an audit manager at Ernst & Young LLP. Ms. Broadfoot holds a B.S. in business administration and accounting from San Diego State University and is a Certified Public Accountant.
|Total Annual Compensation, USD||362,930|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||91,694|
|Fiscal Year Total, USD||454,624|